Pfizer Inc.
NYSEPFE cost to borrow surges 141% in one week to 0.51%, highest level since mid-August as demand for short shares spikes.
A new long-form analysis for PFE this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumThree separate data signals are moving in the same direction on PFE. Short sellers have retreated further. The options market has grown more call-heavy. Borrow costs have halved. Together, they describe a lending and…
Snapshot as of 20 Sept 2026
PFE has extended its recovery to close at $27.25, up 8.8% over the past month, and the insider buying story that defined last week's note has grown more compelling — the CEO himself stepped in on August 12. Albert…
PFE heads into mid-August with an unusual confluence: short sellers are cutting positions at pace, directors are stepping in with near-seven-figure purchases, and the Street is grinding targets lower — all at the same…
Pfizer heads into its August 4 earnings event carrying an unusual distinction: short sellers rebuilt aggressively after the July 28 beat, and that positioning has barely softened in the days since. Short interest tells…
Pfizer delivered its Q2 print on July 28 and the stock rose — yet short sellers added positions aggressively in the same week, creating the week's defining tension. The short interest story is the standout here. SI…
Pfizer heads into its July 28 earnings report with the Street in a quiet retreat — analysts cutting targets but holding ratings, while positioning data shows no particular stress in either direction. The most telling…
PFE heads into its July 28 earnings with shorts continuing to unwind, the Street growing more defensive, and the stock stuck near multi-year lows — a combination that makes the next few weeks more about fundamental…
PFE enters July with a notable reversal in the short-selling story — bears have pulled back sharply over the past week, yet the stock has continued sliding, closing at $24.08 after an 8% drop over the past month. The…
PFE heads into its July 28 earnings report with short sellers adding positions at the fastest pace in months, even as the stock drops to its lowest levels of the year. Short interest is the standout story this week.…
Pfizer enters the week with a curious split: the stock is quietly grinding higher, up 0.6% on the week to $25.70, yet short sellers have been adding positions at their fastest monthly pace in months. Short interest is…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PFE — free to start on ORTEX.
Sign up for free →Open PFE on ORTEX